To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
26
Oral daily dosing for 14 weeks
Mochida Investigational sites
Tokyo, Japan
Pharmacodynamics (Amount of uric acid excreted in urine)
Time frame: 2-week
Pharmacodynamics (Amount of uric acid excreted in urine)
Time frame: 6-week
Pharmacodynamics (Amount of uric acid excreted in urine)
Time frame: 10-week
Pharmacodynamics (Amount of uric acid excreted in urine)
Time frame: 14-week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.